Geron Corporation
Combination treatment for hematological cancers
Last updated:
Abstract:
The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
Status:
Grant
Type:
Utility
Filling date:
28 Jul 2017
Issue date:
22 Mar 2022